<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637403</url>
  </required_header>
  <id_info>
    <org_study_id>100.2.C.002</org_study_id>
    <nct_id>NCT00637403</nct_id>
  </id_info>
  <brief_title>Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Assess the Effect of Renal Impairment on the Pharmacokinetic Characteristics, Safety, and Tolerability of Megestrol Acetate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>SFBC Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the pharmacokinetics and safety of megestrol acetate after a single oral 300 mg
      dose of megestrol acetate concentrated suspension in healthy subjects, and subjects with
      varying degrees of renal impairment
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty finding the required subject population
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic blood samples</measure>
    <time_frame>predose and serially through 264 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine collection</measure>
    <time_frame>Predose and serially through 264 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with mild renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with moderate renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with severe renal impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Megestrol acetate concentrated suspension in subjects with end stage renal disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr &gt;80 mL/min)</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)</description>
    <arm_group_label>II</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - &lt;50 mL/min)</description>
    <arm_group_label>III</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr &lt;30 mL/min and not on hemodialysis)</description>
    <arm_group_label>IV</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol acetate concentrated suspension 125 mg/mL</intervention_name>
    <description>Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose</description>
    <arm_group_label>V</arm_group_label>
    <other_name>Megace ES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Subjects with Normal Renal Function

          1. BMI ≥18 kg/m2 and ≤35 kg/m2

          2. Females of child-bearing potential must use an adequate and reliable method of
             contraception. Postmenopausal females must be postmenopausal ≥1 year and have elevated
             serum FSH

          3. Able to provide written informed consent

          4. Normal renal function, defined as estimated creatinine clearance (CLcr) &gt;80 mL/min at
             screening

        Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD

        Meet inclusion criteria 1 through 3 for healthy subjects and the following criteria:

          1. Renal impairment defined as creatinine clearance &lt;80 mL/min as determined using the
             Cockroft-Gault formula. Subjects grouped according to degree of renal dysfunction:
             mild (CLcr = &gt;50 and ≤80 mL/min), moderate (CLcr = &gt;30 and ≤50 mL/min), or severe
             (CLcr = ≤30 mL/min)

          2. Renal Impairment subjects must have evidence of stable renal impairment. Defined as
             having CLcr values within 25% of each other from 2 separately measured serum
             creatinine clearances using the Cockroft-Gault formula

          3. ESRD subjects require hemodialysis for at least 3 months

          4. Subjects with renal impairment or ESRD may have clinical laboratory test result
             deviations that are judged by the Investigator to be consistent with the renal
             condition of the subject or of no additional clinical significance for this study

          5. Subjects with renal impairment or ESRD, must have stable underlying medical conditions
             for at least 90 days prior to the start of study participation

          6. Renal impaired subjects may smoke up to 5 cigarettes per day

        Exclusion Criteria:

        Healthy Subjects with Normal Renal Function

          1. Clinically significant (history of or active) cardiac, hepatic, renal, pulmonary,
             endocrine, neurological, infectious, gastrointestinal, hematologic, oncologic, or
             psychiatric disease that could put the subject at increased risk or could interfere
             with the objectives of the study

          2. Presence of any screening laboratory values outside the range of normal values and
             deemed clinically significant by the Investigator

          3. Use of a prescription drug within 14 days of study start, a non-prescription drug
             within 7 days of study start, or need of concomitant medication during the study

          4. Use of any drugs or herbal products known to inhibit or induce liver enzymes involved
             in drug metabolism (CYP P450) within 30 days prior to 1st dose

          5. History of allergic reaction or serum sickness to any drug or drug metabolites

          6. Whole blood donation within 56 days prior to the first MA-CS dose or plasma donation
             within 7 days prior to the first MA-CS dose

          7. Positive test for HIV antibody or hepatitis B surface antigen (positive HIV or
             hepatitis C antibody for ESRD subjects are acceptable)

          8. Presence of drugs of abuse and/or alcohol

          9. Participation in another investigational drug study within 30 days prior to the first
             MA-CS dose

         10. History of recent drug abuse or alcohol addiction during past 2 years

         11. Pregnant or breastfeeding

         12. Consumption of grapefruit containing foods and beverages within 7 days prior to the
             first MA-CS dose

         13. History of recurrent thromboembolic events, a thromboembolic event in past three
             months, or those still receiving long-term anticoagulation for thromboembolism

        Subjects with Mild, Moderate, or Severe Renal Impairment or ESRD

        Excluded if subjects meet exclusion criteria 4 through 13 for healthy subjects and the
        following criteria:

          1. Unstable disease defined as concurrent medical conditions that change significantly
             within 90 days

          2. Changes in concomitant medications within 14 days prior to first dose administration
             or expected changes during study participation

          3. Subjects with a renal transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth C Lasseter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn D. Kramer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Par Pharmaceutical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC International</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal impairment</keyword>
  <keyword>end stage renal disease</keyword>
  <keyword>megestrol acetate</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>renal dialysis</keyword>
  <keyword>kidney failure, chronic</keyword>
  <keyword>renal insufficiency</keyword>
  <keyword>Megace ES</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

